Table 4 Pathway analysis of HOXD9 target gene networks.
Source | Pathway* | Ovarian HOXD9 network | Fallopian HOXD9 network | ||
|---|---|---|---|---|---|
% of pathway involved | FDR | % of pathway involved | FDR | ||
KEGG | |||||
Focal adhesion | 14 | 1.9 × 10−4 | 9 | 1.9 × 10−7 | |
TGF-beta signalling pathway | 9 | 2.3 × 10−3 | 11 | 5.1 × 10−3 | |
Ingenuity | |||||
FAK signalling | 5 | 6.9 × 10−3 | 12 | 6.5 × 10−6 | |
ERK5 signalling | 5 | 1.8 × 10−2 | 13 | 3 × 10−5 | |
RAR activation | 5 | 1.9 × 10−4 | 7 | 6 × 10−5 | |
TGF-beta signalling | 7 | 2.4 × 10−4 | 9 | 2.1 × 10−4 | |
Hepatic fibrosis/hepatic stellate cell activation | 8 | 4 × 10−12 | 6 | 5.5 × 10−4 | |
Cell cycle: G1/S checkpoint regulation | 8 | 4.6 × 10−4 | 9 | 1.1 × 10−3 | |
Chronic myeloid leukaemia signalling | 6 | 2.7 × 10−4 | 8 | 1.3 × 10−3 | |
Pancreatic adenocarcinoma signalling | 5 | 2.4 × 10−3 | 7 | 2.5 × 10−3 | |
Virus entry via endocytic pathways | 6 | 1.2 × 10−3 | 7 | 4.3 × 10−3 | |
Growth hormone signalling | 6 | 3.5 × 10−3 | 7 | 6.6 × 10−3 | |
Caveolar-mediated endocytosis signalling | 7 | 6 × 10−4 | 7 | 7.7 × 10−3 | |
Cyclins and cell cycle regulation | 6 | 7.2 × 10−4 | 6 | 1.1 × 10−2 | |
Antiproliferative role of TOB in T-cell signalling | 12 | 3 × 10−3 | 12 | 1.2 × 10−2 | |
Semaphorin signalling in neurons | 6 | 1.2 × 10−2 | 8 | 1.3 × 10−2 | |
Remodelling of epithelial adherens junctions | 6 | 3.4 × 10−3 | 6 | 2.6 × 10−2 | |
VDR/RXR activation | 5 | 5.1 × 10−3 | 5 | 3.9 × 10−2 | |
